Bicycle Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Bicycle Therapeutics
BCYC Stock  USD 6.42  0.10  1.53%   
Bicycle Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bicycle Therapeutics' valuation are provided below:
Gross Profit
-210.9 M
Market Capitalization
452.3 M
Enterprise Value Revenue
21.2178
Revenue
28.3 M
Earnings Share
(3.62)
We have found one hundred twenty available fundamental signals for Bicycle Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Bicycle Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 31, 2026, Market Cap is expected to decline to about 559.2 M. In addition to that, Enterprise Value is expected to decline to about 138.5 M

Bicycle Therapeutics Total Revenue

42.59 Million

Check Bicycle Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicycle Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 41.4 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 8.7 M, as well as many indicators such as Price To Sales Ratio of 52.04, Dividend Yield of 0.0 or PTB Ratio of 1.12. Bicycle financial statements analysis is a perfect complement when working with Bicycle Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Bicycle Stock
Check out the analysis of Bicycle Therapeutics Correlation against competitors.
For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

Bicycle Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.2 B1.1 B306.4 M
Slightly volatile
Other Current Liabilities43.2 M41.1 M13.1 M
Slightly volatile
Total Current Liabilities81.2 M77.3 M27.2 M
Slightly volatile
Property Plant And Equipment Net13.1 M19.8 M8.4 M
Slightly volatile
Accounts Payable19.1 M18.2 M5.6 M
Slightly volatile
Cash1.1 B1 B275.4 M
Slightly volatile
Non Current Assets Total17.5 M32.5 M11.6 M
Slightly volatile
Non Currrent Assets Other12.7 M12.1 M3.6 M
Slightly volatile
Other Assets10.2 M9.7 M3.4 M
Slightly volatile
Cash And Short Term Investments1.1 B1 B275.4 M
Slightly volatile
Net Receivables43.1 M41 M13.1 M
Slightly volatile
Common Stock Shares Outstanding70.3 M66.9 M27.4 M
Slightly volatile
Liabilities And Stockholders Equity1.2 B1.1 B306.4 M
Slightly volatile
Capital Surpluse235.5 M224.3 M96.2 M
Slightly volatile
Other Current Assets16.2 M15.4 M5.9 M
Slightly volatile
Total Liabilities124.8 M188.4 M79.8 M
Slightly volatile
Total Current Assets1.1 B1.1 B293.8 M
Slightly volatile
Common Stock1.1 M1 M284.6 K
Slightly volatile
Property Plant Equipment39.6 M37.7 M12.2 M
Slightly volatile
Current Deferred Revenue12.3 M11.7 M8.3 M
Slightly volatile
Non Current Liabilities Total101.8 M111.1 M102.1 M
Pretty Stable
Property Plant And Equipment Gross20.8 M41.6 M13.1 M
Slightly volatile
Non Current Liabilities Other2.6 M1.3 M1.5 M
Slightly volatile
Net Working Capital1 B990.6 M289.1 M
Slightly volatile
Capital Stock1.1 M1 M287.8 K
Slightly volatile
Short and Long Term Debt Total10.4 M10.9 M11.7 M
Slightly volatile
Capital Lease Obligations10.2 M10.9 M5.5 M
Slightly volatile

Bicycle Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income41.4 M39.4 M8 M
Slightly volatile
Depreciation And Amortization8.7 M8.3 M2.4 M
Slightly volatile
Selling General Administrative86.3 M82.2 M27.4 M
Slightly volatile
Selling And Marketing Expenses574.3 K826.9 K554.6 K
Slightly volatile
Other Operating Expenses296 M281.9 M87.8 M
Slightly volatile
Research Development208.9 M198.9 M60.2 M
Slightly volatile
Cost Of Revenue208.9 M198.9 M51.7 M
Slightly volatile
Total Operating Expenses57.5 M83 M40.6 M
Slightly volatile
Reconciled Depreciation8.7 M8.3 M2.4 M
Slightly volatile

Bicycle Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation46 M43.8 M12.4 M
Slightly volatile
Begin Period Cash Flow636.3 M606 M174 M
Slightly volatile
Depreciation8.7 M8.3 M2.4 M
Slightly volatile
Capital Expenditures1.3 M1.4 M2 M
Slightly volatile
Total Cash From Financing Activities627.6 M597.7 M155.6 M
Slightly volatile
End Period Cash Flow1.1 B1 B275.6 M
Slightly volatile
Change To Netincome26.9 M25.6 M8.8 M
Slightly volatile
Issuance Of Capital Stock657 M625.7 M160.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio52.0426.5758.7744
Slightly volatile
Days Sales Outstanding469424472
Slightly volatile
Stock Based Compensation To Revenue0.640.970.5748
Slightly volatile
Capex To Depreciation0.190.21.2648
Very volatile
Payables Turnover8.829.867.1027
Slightly volatile
Sales General And Administrative To Revenue1.861.822.5885
Slightly volatile
Research And Ddevelopement To Revenue3.434.414.8528
Slightly volatile
Capex To Revenue0.03820.04030.3779
Slightly volatile
Cash Per Share7.5313.66.4111
Slightly volatile
Days Payables Outstanding36.4138.331.1 K
Slightly volatile
Income Quality0.691.120.7358
Pretty Stable
Net Debt To EBITDA2.734.752.4935
Slightly volatile
Current Ratio7.0312.436.845
Slightly volatile
Receivables Turnover0.780.890.8359
Slightly volatile
Debt To Equity0.01310.01380.0482
Slightly volatile
Capex Per Share0.01810.01910.0785
Slightly volatile
Revenue Per Share0.480.550.4069
Slightly volatile
Interest Debt Per Share0.160.170.4666
Slightly volatile
Debt To Assets0.01080.01140.034
Slightly volatile
Operating Cycle469424472
Slightly volatile
Days Of Payables Outstanding36.4138.331.1 K
Slightly volatile
Ebt Per Ebit1.10.951.0036
Pretty Stable
Long Term Debt To Capitalization0.110.08790.1166
Slightly volatile
Total Debt To Capitalization0.01290.01360.0436
Slightly volatile
Debt Equity Ratio0.01310.01380.0482
Slightly volatile
Quick Ratio7.0312.436.845
Slightly volatile
Net Income Per E B T1.091.121.0059
Slightly volatile
Cash Ratio6.4211.776.1856
Slightly volatile
Days Of Sales Outstanding469424472
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.261.161.114
Pretty Stable
Fixed Asset Turnover2.152.361.8068
Pretty Stable
Debt Ratio0.01080.01140.034
Slightly volatile
Price Sales Ratio52.0426.5758.7744
Slightly volatile
Asset Turnover0.06140.04240.0438
Slightly volatile

Bicycle Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap559.2 M579.2 M365.5 M
Slightly volatile
Enterprise Value138.5 M145.8 M158 M
Slightly volatile

Bicycle Fundamental Market Drivers

Bicycle Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bicycle Therapeutics Financial Statements

Bicycle Therapeutics stakeholders use historical fundamental indicators, such as Bicycle Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Bicycle Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bicycle Therapeutics' assets and liabilities are reflected in the revenues and expenses on Bicycle Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bicycle Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue11.7 M12.3 M
Total Revenue40.6 M42.6 M
Cost Of Revenue198.9 M208.9 M
Stock Based Compensation To Revenue 0.97  0.64 
Sales General And Administrative To Revenue 1.82  1.86 
Research And Ddevelopement To Revenue 4.41  3.43 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.55  0.48 
Ebit Per Revenue(6.84)(7.18)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CCitigroup
SSentinelOne
When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:
How To Invest In Bicycle
Details
Is Bicycle Stock a good investment?
Details
What is Bicycle Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Bicycle Therapeutics Correlation against competitors.
For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Will Biotechnology sector continue expanding? Could Bicycle diversify its offerings? Factors like these will boost the valuation of Bicycle Therapeutics. Projected growth potential of Bicycle fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bicycle Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(3.62)
Revenue Per Share
0.409
Quarterly Revenue Growth
3.385
Return On Assets
(0.21)
Return On Equity
(0.35)
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Bicycle Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bicycle Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bicycle Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY